Dyne Therapeutics, Inc.
$20.02
▲
4.09%
2026-04-21 06:32:00
www.dyne-tx.com
NMS: DYN
Explore Dyne Therapeutics, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$3.37 B
Current Price
$20.02
52W High / Low
$25 / $7.38
Stock P/E
—
Book Value
$5.89
Dividend Yield
—
ROCE
-41.2%
ROE
-55.71%
Face Value
—
EPS
$-3.47
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
258
Beta
1.28
Debt / Equity
17.41
Current Ratio
22.25
Quick Ratio
22.25
Forward P/E
-6.16
Price / Sales
—
Enterprise Value
$2.14 B
EV / EBITDA
-4.59
EV / Revenue
—
Rating
Strong Buy
Target Price
$38.19
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Skye Bioscience, Inc. | $0.78 | — | $26.15 M | — | -289.25% | -1.27% | $5.75 / $0.57 | $0.6 |
| 2. | Nautilus Biotechnology, Inc. | $2.96 | — | $383.49 M | — | -36.49% | -32.27% | $4.31 / $0.62 | $1.24 |
| 3. | Prothena Corporation plc | $10.79 | — | $583.55 M | — | -64.54% | -63.62% | $11.69 / $4.32 | $5.21 |
| 4. | Protagonist Therapeutics, Inc. | $104.42 | — | $6.74 B | — | -25.39% | -20.18% | $107.84 / $41.28 | $9.82 |
| 5. | Adial Pharmaceuticals, Inc. | $1.63 | — | $2.33 M | — | -147.82% | -1.71% | $687.5 / $1.54 | $4.75 |
| 6. | Enveric Biosciences, Inc. | $3.65 | — | $3.44 M | — | -210.04% | -3.04% | $17.84 / $1.71 | $3.94 |
| 7. | Traws Pharma, Inc. | $1.39 | — | $14.12 M | — | -185.49% | -10.6% | $3.27 / $0.97 | $0.64 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | |
|---|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M | 0 M |
| Operating Profit | -116.13 M | -113.89 M | -115.79 M | -122.37 M | -97.11 M |
| Net Profit | -111.95 M | -108.04 M | -110.86 M | -115.36 M | -89.54 M |
| EPS in Rs | -0.68 | -0.65 | -0.67 | -0.7 | -0.54 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M |
| Operating Profit | -468.18 M | -343.89 M | -242.16 M | -170.96 M |
| Net Profit | -446.21 M | -317.42 M | -235.94 M | -168.1 M |
| EPS in Rs | -2.7 | -1.92 | -1.43 | -1.02 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 1.19 B | 691.23 M | 165.08 M | 306.32 M |
| Total Liabilities | 214.83 M | 61.4 M | 73.79 M | 53.96 M |
| Equity | 972.13 M | 629.84 M | 91.29 M | 252.36 M |
| Current Assets | 1.13 B | 659.28 M | 129.38 M | 265.59 M |
| Current Liabilities | 50.62 M | 42.26 M | 51.09 M | 28.09 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -403.21 M | -292.37 M | -188.16 M | -153.65 M |
| Investing CF | -28.75 M | -204.08 M | 83.31 M | 87.2 M |
| Financing CF | 890.31 M | 809.89 M | 54.32 M | 37.39 M |
| Free CF | -423.92 M | -294.75 M | -188.89 M | -156.71 M |
| Capex | -20.71 M | -2.38 M | -0.73 M | -3.07 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | — | — | — | — |
| Earnings Growth % | -34.54% | -40.36% | — | — |
| Profit Margin % | — | — | — | — |
| Operating Margin % | — | — | — | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | — | — | — | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.